Table 1 Susceptibility of 63 Corynebacterium striatum clinical isolates to 16 antimicrobial agents.
Antimicrobial agent | Range (mg/L) | MIC50 | MIC90 | Breakpoint | Resistant | Intermediate | Total (%) R | ||
|---|---|---|---|---|---|---|---|---|---|
S | I | R | |||||||
Amikacin | 0.06–64 | 0.06 | 1 | ≤16 | 32 | ≥64 | 3 | 0 | 3 (4.8%) |
Gentamicin | 0.06–64 | 0.06 | 2 | ≤4 | 8 | ≥16 | 3 | 1 | 4 (6.3%) |
Kanamicin | 0.016–256 | 0.125 | >64 | ≤16 | 32 | ≥64 | 10 | 1 | 11 (17.5%) |
Tobramicin | 0.06–64 | 0.06 | 8 | ≤4 | 8 | ≥16 | 3 | 4 | 7 (11.1%) |
Streptomycin | 0.125–64 | 2 | >64 | ≤8 | >16 | 8 | 2 | 10 (15.9%) | |
Erythromycin | 0.06–64 | 0.5 | 8 | ≤0.5 | 1 | ≥2 | 24 | 6 | 30 (47.6%) |
Clindamycin | 0.06–64 | 1 | >64 | ≤0.5 | 2 | ≥4 | 24 | 26 | 50 (79.4%) |
Doxycicline | 0.06–16 | 0.06 | 8 | ≤4 | 8 | ≥16 | 0 | 11 | 11 (17.5%) |
Ciprofloxacin | 0.015–16 | 0.125 | >16 | ≤1 | 2 | ≥4 | 21 | 2 | 23 (36.5%) |
Moxifloxacin | 0.06–16 | 0.06 | >16 | ≤0.5 | 1 | ≥2 | 15 | 7 | 22 (34.9%) |
Penicillin | 0.06–64 | 1 | 16 | ≤0.125 | 52 | 0 | 52 (82.5%) | ||
Cefotaxime | 0.25–256 | 2 | 16 | ≤1 | 2 | ≥4 | 28 | 10 | 38 (60.3%) |
Rifampicin | 0.015–64 | 0.015 | 16 | ≤1 | 2 | ≥4 | 14 | 2 | 16 (25.4%) |
Vancomycin | 0.06–1 | 0.25 | 0.25 | ≤2 | 0 | 0 | 0 | ||
Linezolid | 0.015–1 | 0.25 | 0.5 | ≤4 | ≥8 | 0 | 0 | 0 | |
Daptomycin | 0.015–1 | 0.125 | 0.25 | ≤1 | 0 | 0 | 0 | ||
